American Century Companies Inc. Acquires Shares of 47,329 Enzo Biochem, Inc. (ENZ)
American Century Companies Inc. acquired a new stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 47,329 shares of the medical research company’s stock, valued at approximately $523,000. American Century Companies Inc. owned 0.10% of Enzo Biochem as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Legal & General Group Plc increased its holdings in Enzo Biochem by 10.6% during the second quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after buying an additional 1,022 shares during the period. Trexquant Investment LP purchased a new position in Enzo Biochem in the first quarter worth $115,000. KCG Holdings Inc. purchased a new position in Enzo Biochem in the first quarter worth $141,000. Prudential Financial Inc. purchased a new position in Enzo Biochem in the first quarter worth $149,000. Finally, American International Group Inc. grew its holdings in Enzo Biochem by 7.1% in the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock worth $204,000 after purchasing an additional 1,610 shares during the last quarter. 62.70% of the stock is currently owned by institutional investors.
ENZ has been the topic of several analyst reports. BidaskClub lowered shares of Enzo Biochem from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, June 20th.
Enzo Biochem, Inc. (NYSE ENZ) opened at 10.45 on Wednesday. The firm has a 50-day moving average of $11.08 and a 200 day moving average of $9.80. The stock has a market capitalization of $484.95 million, a price-to-earnings ratio of 14.66 and a beta of 0.92. Enzo Biochem, Inc. has a 12-month low of $4.88 and a 12-month high of $12.04.
Enzo Biochem Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.